

FAX**To** Karen Tyson**Company** USPTO**Fax** 703-872-9411**From** Amy H. Fix**Tel** 919-483-8911 **Fax** 919-483-7988**E-mail** aki27836@glaxowellcome.com**Date** 09-Apr-2002 **Pages** Including cover 5**Subject** Patent No. 5,565,467**GlaxoSmithKline**

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

DOCKET No. G1070US2 Date Mailed 12/20/01 Atty/Secy AHF/AKS
MAILING: CERTIFICATE/EXPRESS MAIL # 12/20/01
Patent
US Serial No.: 5,565,467 Issue Filing Date: 10/16/96
Int'l App. No.: _____ Int'l Filing Date: _____

RECEIPT IS ACKNOWLEDGED FOR THE FOLLOWING:

- | | |
|---|--|
| <input type="checkbox"/> Appln Transmit +1 copy for: <input type="checkbox"/> Provisional <input type="checkbox"/> CIP | <input type="checkbox"/> Copy of Notice to Comply |
| <input type="checkbox"/> Utility <input type="checkbox"/> CONTIN <input type="checkbox"/> DIV <input type="checkbox"/> RCE <input type="checkbox"/> TRADEMARK | <input type="checkbox"/> Statement to Support Filing |
| <input type="checkbox"/> Specification _____ pgs <input type="checkbox"/> Abstract _____ pgs | <input type="checkbox"/> Diskette <input type="checkbox"/> Sequence List |
| <input type="checkbox"/> Dees _____ pgs <input type="checkbox"/> Powers of Atty _____ pgs | <input type="checkbox"/> Appeal Brief _____ pgs |
| <input type="checkbox"/> Drawings _____ Sheet(s)/Figs _____ to _____ | <input type="checkbox"/> Petition _____ pgs |
| <input type="checkbox"/> Assignment _____ pgs & Recordation Cover Sheet | <input type="checkbox"/> Status Request |
| <input type="checkbox"/> Transmit Ltr Nat'l Stage Entry +fee pg (3pgs) | <input type="checkbox"/> 2nd Transmit for Nat'l Stage |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Resp. to Written Opinion |
| <input type="checkbox"/> Form PTO-1449 _____ pgs. <input type="checkbox"/> References | <input type="checkbox"/> Priority Doc # _____ |
| <input type="checkbox"/> Amendment <input type="checkbox"/> Response _____ pgs | <input type="checkbox"/> Notice of Appeal +fee |
| <input type="checkbox"/> Petition for _____ month Extension of Time +1 copy | <input type="checkbox"/> Resp to Restrict Req _____ pgs |
| <input type="checkbox"/> Issue Fee Trans. (Part B) + 1 copy | <input type="checkbox"/> Req to Correct Filing Recpt |
| <input type="checkbox"/> Copy of Notice to File Missing Parts | <input type="checkbox"/> Copy of Filing Receipt |
| <input type="checkbox"/> Request for Nonpublication (1 pg) | <input checked="" type="checkbox"/> Req for Cert of Correct Lpgs |
| <input type="checkbox"/> Authorization to Charge Dep. Acct. # 07-1392 | |
| <input checked="" type="checkbox"/> Cert. of Correction | |
| <input checked="" type="checkbox"/> Previously filed Petition; Statements of inventor; Consent of assignee; | |
| <input type="checkbox"/> Cert. Under 37 CFR 3.73(b); Assignment | |

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)Applicant(s): **Batchelor et al.**

Docket No.

G1070US2

Serial No.

08/405,120

Filing Date

March 16, 1995

Examiner

Group Art Unit

Invention: **ADROSTENONE DERIVATIVE**

I hereby certify that this Request for Certificate of Correction and Certificate of Correction
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The
Commissioner of Patents and Trademarks, Washington, D.C. 20231-0001 on 12/20/01
(Date)

Allyson K. Jacobs

(Typed or Printed Name of Person Mailing Correspondence)

Allyson K. Jacobs

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Batchelor, et al.

Patent No.: 5,565,467

Issued: October 15, 1996

For: ADROSTENONE DERIVATIVE

Commissioner for Patents
Washington, DC 20231

Attn: Certificate of Correction Branch of the Patent Issue Division

REQUEST FOR CERTIFICATE OF CORRECTION

Sir:


Applicants failed to receive a Certificate of Correction for the above-referenced patent from a 1999 Petition to correct inventorship. An appropriate Certificate of Correction is requested.

On May 17, 1999, Applicants filed a Petition for Correction of United States Letters Patent 5,565,467. Applicants requested correction of error, without deceptive intent, of misjoinder of inventors. A copy of Applicants petition, with supporting declarations from the inventors, is attached hereto.

Applicants request a Certificate of Correction to correctly name Kenneth W. Batchelor and Stephen V. Frye as the inventors for United States Letters Patent 5,565,467. Attached hereto is PTO Form PTO/SB/44 (PTO-1050) showing the correct inventorship.

No fee is believed necessary for the above-requested correction. Applicants obtained the prosecution file history for the above-referenced patent. As shown by the USPTO date stamp on the accompanying documents, the error appears to have been on the part of the Office.

Should any fee be necessary, Applicants request that this be considered a petition therefor with authority to charge such fee, or credit any overpayment, to Deposit Account 07-1392. Should any questions arise, Applicants encourage the Office to all the undersigned for expeditious handling.

 Dec. 20, 2001

Amy H. Fix
Attorney for Applicants
Reg. No. 42,616

PTO/SB/44 (08-00)

Approved for use through 09/30/2000. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 5,565,467

DATED : October 15, 1996

INVENTOR(S): Batchelor et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On petition requesting issuance of a certificate of correction of inventorship under 35 U.S.C. § 256, the above-identified patent, through error and without deceptive intent, improperly sets forth inventorship.

Accordingly, the correct inventorship of this patent is: Kenneth W. Batchelor and Stephen V. Frye.

MAILING ADDRESS OF SENDER: Amy H. Fix
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398

PATENT NO. 5,846,976

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.